CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 20 enrolled / 20 target
Drug / intervention
transauricular Vagus Nerve Stimulationdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06006299
NCT06006299Phase 1CompletedOn Track (0.6/mo)Completion was 11mo ago

Investigating the Feasibility of Using taVNS to Treat Insomnia in Individuals With Stage I-IV Breast Cancer

University of Alabama at Birmingham·interventional·Posted Aug 23, 2023·Updated Jun 18, 2026

In Brief

A Phase 1 clinical trial evaluating transauricular Vagus Nerve Stimulation for Breast Cancer and Insomnia. Completed, enrolled 20 participants across 2 sites.

Detailed Summary

In the present study, the investigators aim to investigate feasibility of utilizing noninvasive neuromodulation, specifically taVNS, as a nonpharmacologic approach to address insomnia in patients with stage I-IV breast cancer.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
202420252026
First PostedAug 23, 2023
Enrollment StartSep 26, 2023
Primary CompletionJul 9, 2025
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 2.9 years ago

Arms & Interventions

taVNSexperimental

Participants will use the transauricular Vagus Nerve Stimulator provided to them by the lab for 14 days, 15 minutes prior to sleeping. Data will be collected via surveys, interviews, and Fitbit wear over the course of 2 months. A sleep diary will be kept to record sleep quality.

Device: transauricular Vagus Nerve Stimulation

Interventions

transauricular Vagus Nerve Stimulationdevice

Transcutaneous auricular vagus nerve stimulation (taVNS) is a form of transcutaneous electrical nerve stimulation (TENS) applied to peripheral nerves, considered a low-risk procedure. It involves the use of standard neurostimulation electrodes placed on the surface of the external ear. The taVNS method delivers low-intensity, pulsed electrical currents with a peak current amplitude of \<4 mA, which is significantly lower than those used in most over-the-counter TENS devices for pain relief or muscle stimulation. By targeting the auricular branches of the vagus nerve, taVNS aims to stimulate specific neural pathways associated with various indications and intended uses. This non-invasive approach has broad applications in research, medical device treatments, health products, and cosmetic or lifestyle products.